Skip to content
RecallWatchMedical Device Safety
Class IIOngoingZ-0036-2026

W L Gore & Associates, Inc. recalls GORE ACUSEAL Vascular Graft

W L Gore & Associates, Inc.Flagstaff, AZ, United StatesReported Oct 8, 2025 · 9 months ago
Legal News Analyst ·

Reason for recall

Reports of vascular graft delamination, which may lead to reduced access flow; cannulation difficulties; bleeding or bruising; and harms related to reintervention procedures, so Instructions for Use will be updated to modify existing warning to 1) further clarify techniques that may contribute to the risk of delamination, 2) Addition of delamination to device-related adverse event section.

Affected product

Check your device

Enter a lot, serial, REF, or UDI number from your device's label to check it against this recall's listed codes.

GORE ACUSEAL Vascular Graft17 codes
  • ECH050020J
  • ECH050020W
  • ECH050050J
  • ECH050050W
  • ECH060010A
  • ECH060020A
  • ECH060020J
  • ECH060020W
  • ECH060040
  • ECH060040A
  • ECH060040W
  • ECH060050A
  • ECH060050J
  • ECH460045A
  • ECH460045J
  • ECH470045
  • ECH470045A

used with Instructions for Use.

Lot / code information

UDI
ECH050020J/04993024010758, ECH050020W/00733132635450, ECH050050J/04993024010772, ECH050050W/00733132635474, ECH060010A/00733132622573, ECH060020A/00733132622597 — +11 moreShow all
ECH050020J/04993024010758, ECH050020W/00733132635450, ECH050050J/04993024010772, ECH050050W/00733132635474, ECH060010A/00733132622573, ECH060020A/00733132622597, ECH060020J/04993024009967, ECH060020W/00733132634729, ECH060040/00733132605347, ECH060040A/00733132605354, ECH060040W/00733132619719, ECH060050A/00733132626960, ECH060050J/04993024009981, ECH460045A/00733132634811, ECH460045J/04993024010789, ECH470045/00733132626977, ECH470045A/00733132634811. Product with a
Serial #
that includes and falls within the range of 6597081PP001 and 9853822PP024. Instructions for Use MD183888 Revision 4

What the firm is doing

On 8/26/2025, correction notices were mailed to Vascular Surgeons and other physicians who were informed of the following: No action is required for patients who currently have the device implanted; however, please be aware of delamination as a potential cause of occlusion should clinical issues arise in the future. Management of patients with suspected or confirmed delamination should be guided by the clinical judgment of the treating physician, with careful consideration of the risks and benefits of each treatment option in the context of the individual circumstance. Instructions for use will be updated to include the following: When performing reinterventions on the GORE ACUSEAL Vascular Graft, avoid the use of oversized balloons. A possible complication which may occur with the use of the GORE ACUSEAL Vascular Graft is delamination. Delamination may result in partial or complete occlusion due to hemodynamically significant stenosis or thrombosis and related serious harms, including additional interventions to resolve. IFUs are available at: https://eifu.goremedical.com/ In addition, customers were asked to do the following: 1) Complete and return the acknowledgement form via email to wlgore3081@sedgwick.com 2) This notice needs to be shared with those who should be aware within your institution or to any organization where potentially affected devices have been transferred (as appropriate). To report an event to firm, email: medcomplaints@wlgore.com Questions can be directed to firm Customer Service (email: MPDCustomerCare@wlgore.com or by phone at 800-528-8763

DistributionShow details

US: OR, AL, OH, MD, VA, CA, FL, NC, OK, MA, MO, AZ, TX, IL, GA, PA, NH, HI, MN, MS, KY, ID, LA, NJ, TN, DE, IN, MI, WI, NY, DC, SC, CT, NE, IA, WA, AR, NV, WV, AK, UT, ND, KS, CO, ME, MT, NM, SD, PR, WY, RI. OUS: PANAMA, CANADA, CHINA, TAIWAN, GERMANY, SLOVENIA, NORWAY, UNITED KINGDOM, ITALY, SPAIN, FINLAND, NETHERLANDS, SWEDEN, FRANCE, UNITED ARAB EMIRATES, DENMARK, PORTUGAL, AUSTRIA, SWITZERLAND, BELGIUM, TURKIYE, SLOVAK REPUBLIC, CYPRUS, SAUDI ARABIA, SOUTH AFRICA, LUXEMBOURG, FRENCH GUIANA, ANDORRA, IRELAND, NEW CALEDONIA, POLAND, ISRAEL, GREECE, GUADELOUPE, CROATIA, REUNION, BAHRAIN, HUNGARY, JAPAN

Class IIWhat this means

Use of the product may cause temporary or medically reversible adverse health consequences.

Sources & references

Taylor Coteus
Legal News Analyst

Taylor Coteus is RecallWatch's Legal News Analyst, covering FDA medical-device enforcement and patient-safety litigation. He reviews every recall against the FDA's official openFDA record before it is published and is responsible for corrections and editorial accuracy.

More Class II recalls